{"doi":"10.54235/9789939879925","title":"Pilot implementation of USI FORTIMAS Methodology for Assessment and Tracking Effective Coverage of the National Salt lodization Program and iodine status of pregnant women in the Republic of Armenia","abstract":"To enable public and private sector stakeholders of the national salt iodization program in Armenia to be able to confirm high population coverage of well iodized salt and the associated adequate iodine status of the population systematically and at a substantially lower cost than typical population-based representative surveys, the IGN supported the “pilot” implementation of the FORTIMAS (Fortification Monitoring and Surveillance) methodology, adapted to tracking “effective coverage” of iodized salt, in Armenia. Primary analysis of non-probabilistic data showed high (92%) household coverage of adequately iodized salt and optimum (175.3 µg/L) median urinary iodine concentration among 1st trimester pregnant women, across purposively selected sentinel sites. Secondary analysis of data on production, imports and distribution of iodized salt indicated consistently high expected and assessed population coverage of iodized salt during the past decade. The prevalence of neonatal TSH levels above 5 mUI/L (an indicator of iodine status among pregnant women) over past 12 years was less than 3% with a general trend of decreasing from 2.35% in 2017 to 1.39% in 2023. The cost of implementation of the FORTIMAS approach as an initial round of “annual” iodized salt program monitoring and surveillance in Armenia, was only a fraction of that of a typical nationally representative salt iodization/population iodine status survey. Furthermore, because the overall framework of a potential “Armenia FORTIMAS System” has been developed under this project, it may be estimated that about 10 annual rounds of salt iodization program monitoring and surveillance may be carried out in Armenia int the future, at about the same cost as one nationally representative salt iodization program survey.","journal":null,"year":2024,"id":503431,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9495,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1353309,"name":"Г. А. Герасимов","orcid":"0000-0002-6299-7219","position":1,"is_corresponding":false},{"id":1353310,"name":"Ibrahim Parvanta","orcid":"0000-0002-4635-4803","position":2,"is_corresponding":false},{"id":1353308,"name":"H. Ts. Aslanyan","orcid":"0000-0002-4615-844X","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:10:31.826282Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}